Pancreatic Cancer Research

ResearcherHenry Ford Health + Michigan State University Health SciencesActive in the last 2 years

Nina G. Steele

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1564-3562; OpenAlex author ID A5019403449; NIH RePORTER profile ID 15623719. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 2)
Trials
0
Grants
2
Labs led
2
Collaborators
143
Papers, trials and grants by year

2020: 4 papers · 2021: 5 papers, 1 grant · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers, 1 grant · 2025: 5 papers · 2026: 5 papers

Papers 28

  1. Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
  2. Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments. Last author DOI 10.1158/0008-5472.can-25-2748↗
  3. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  4. A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer Co-author DOI 10.64898/2026.05.20.726559↗
  5. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  6. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2024.12.003↗
  7. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  8. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Last author DOI 10.1158/1078-0432.ccr-24-2183↗
  9. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  10. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Co-author DOI 10.1172/jci.insight.174264↗
  11. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer Co-author DOI 10.1101/2024.05.15.594354↗
  12. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  13. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  14. Multi-omics analysis of metastatic pancreatic cancer reveals an immunosuppressive landscape. Co-author DOI 10.1016/j.medj.2023.09.005↗
  15. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0547↗
  16. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  17. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  18. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  19. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Co-author DOI 10.7554/elife.73796↗
  20. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Co-author DOI 10.1016/j.jcmgh.2020.08.011↗
  21. Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Co-author DOI 10.1038/s41388-021-01771-z↗
  22. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  23. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  24. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. First author DOI 10.26508/lsa.202000935↗
  25. Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition. Co-author DOI 10.1038/s41598-020-67814-9↗
  26. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  27. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-20-1692↗
  28. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗

Grants 2

  1. Investigating Cellular Communication in the Tumor Microenvironment in Pancreatic Cancer R00CA263154↗
  2. Investigating Cellular Communication in the Tumor Microenvironment in Pancreatic Cancer K99CA263154↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Howard C. Crawford · 15 shared papers, 2020–2026 · strength 2.11
  2. Marina Pasca di Magliano · 16 shared papers, 2020–2025 · strength 2.07
  3. Samantha B. Kemp · 11 shared papers, 2020–2025 · strength 1.44
  4. Ian M. Loveless · 7 shared papers, 2025–2026 · strength 1.41
  5. Eileen S. Carpenter · 8 shared papers, 2020–2025 · strength 1.04
  6. Filip Bednar · 8 shared papers, 2020–2025 · strength 0.99
  7. Costas Andreas Lyssiotis · 8 shared papers, 2020–2025 · strength 0.90
  8. Zeribe C. Nwosu · 7 shared papers, 2021–2025 · strength 0.84
  9. Daniel James Salas-Escabillas · 5 shared papers, 2021–2026 · strength 0.83
  10. Kailee M. Hartway · 3 shared papers, 2023–2026 · strength 0.77
  11. Katelyn L. Donahue · 6 shared papers, 2020–2025 · strength 0.77
  12. Yaqing Zhang · 7 shared papers, 2021–2022 · strength 0.76
  13. Debora Barbosa Vendramini Costa · 4 shared papers, 2024–2026 · strength 0.76
  14. Ralph A. Francescone III · 4 shared papers, 2024–2026 · strength 0.76
  15. Timothy L. Frankel · 6 shared papers, 2020–2025 · strength 0.66
  16. Christopher J. Halbrook · 5 shared papers, 2021–2026 · strength 0.65
  17. Rosa Elena Menjivar · 4 shared papers, 2021–2025 · strength 0.60
  18. Faiyaz Notta · 3 shared papers, 2025–2026 · strength 0.59
  19. Janusz Franco‐Barraza · 3 shared papers, 2023–2026 · strength 0.54
  20. Edna Cukierman · 3 shared papers, 2023–2026 · strength 0.54
  21. Megan T. Hoffman · 4 shared papers, 2021–2025 · strength 0.51
  22. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  23. Vaibhav Sahai · 4 shared papers, 2020–2025 · strength 0.49
  24. Benjamin Allen · 4 shared papers, 2020–2025 · strength 0.47
  25. Rima Singh · 3 shared papers, 2022–2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.